PubMed Health⌕ Search

PubMed · 9266125

Treatment options for benign prostatic hyperplasia.

Abstract

OBJECTIVE: To examine current treatment options for benign prostatic hyperplasia with emphasis on randomized, clinical trials and our current management approach. QUALITY OF EVIDENCE: Benign prostatic hyperplasia remains difficult to define clinically or measure objectively. As a result, research has been fairly weak. With newer treatments, however, more definitive studies have been reported. MAIN FINDINGS: Transurethral resection of the prostate remains the criterion standard for severe disease. Watchful waiting, medical management, or early surgical intervention are all valid options for moderate disease and should be tailored to the characteristics and desires of individual patients. Recent minimally invasive surgical techniques, such as microwave and laser surgery, have not yet achieved the quality of evidence to be generally recommended. CONCLUSIONS: Management of benign prostatic hyperplasia should be individualized to patients' circumstances and personal choices.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A J Portis, D R Mador. 1997. Treatment options for benign prostatic hyperplasia.. https://pubmed.ncbi.nlm.nih.gov/9266125/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial.

BACKGROUND: Use of 5 mg/day finasteride (Proscar) for benign prostatic hyperplasia is known to affect serum concentrations of prostate-specific antigen (PSA). When men taking this treatment undergo screening for prostate cancer, a compensatory adjustment of the PSA concentration (to multiply the value by two) is recommended. Whether this recommendation should apply to men taking 1 mg/day finasteride (Propecia) for the treatment of androgenic alopecia is unknown. We aimed to assess the effect of 1 mg/day finasteride on serum PSA in men aged 40-60 years with male-pattern hair loss. METHODS: Between March 13, 1998, and Jan 12, 2000, 355 men aged 40-60 years with male-pattern hair loss were stratified by age decade (40-49 years and 50-60 years), and randomised in a ratio of four to one to 1 mg/day finasteride or placebo. The primary endpoint was the effect of this treatment for 48 weeks on serum PSA concentration compared with placebo. This trial is in the process of being registered on the US National Institutes of Health website . Analyses were according to protocol. FINDINGS: Within 48 weeks of randomisation, men aged 40-49 years and 50-60 years who were assigned 1 mg/day finasteride had a median decrease in serum PSA concentration of 40% (95% CI 34-46) and 50% (44-57), respectively. In men assigned placebo, the median changes were 0% [-14 to 14] and a median increase of 13% [2 to 24], respectively. INTERPRETATION: In men aged 40-60 years, 1 mg/day finasteride for 48 weeks lowers serum PSA concentration. Therefore, the existing recommendation for the adjustment of serum PSA concentration in prostate-cancer screening in men taking 5 mg/day finasteride should also apply to men taking the 1 mg/day preparation for male-pattern hair loss. Research is needed to assess the effect of 1 mg/day finasteride preparation beyond 48 weeks of treatment.

5-alpha Reductase Inhibitors↗

The anxiolytic effect of pregnancy in rats is reversed by finasteride.

Several studies have shown the influence of the oestrous cycle on anxiety levels and the important role of progesterone in this effect. The metabolism of this steroid hormone yields neuroactive steroids among them allopregnanolone (alloP) and allotetrahydrodeoxycorticosterone (alloTHDOC), which bind to GABAA receptors and have anxiolytic effects. Considering that during pregnancy there is an increase in levels of both progesterone and its metabolites, the main objectives of this work were: (1) to assess changes in anxiety levels during pregnancy and (2) to verify the role of alloP and alloTHDOC in this process using finasteride, an inhibitor of 5alpha-reductase, the enzyme responsible for their synthesis. The results showed a significant reduction in anxiety levels on the 19th day of pregnancy, which was reversed by finasteride, suggesting a role for alloP and alloTHDOC in the anxiolytic process.

5-alpha Reductase Inhibitors↗